Last updated: March 2, 2026
What is the Scope of Patent ES2906551?
Patent ES2906551 pertains to a specific pharmaceutical invention. It generally covers a novel compound, formulation, or therapeutic method, with details located in the claims section. The patent was filed to protect the innovative aspects related to this invention's chemical structure, pharmaceutical composition, or method of treatment.
The patent claims are limited geographically to Spain but may have counterparts internationally. The patent's scope is determined by the claims that specify the invention's boundaries, including functional, structural, or process features.
What Are the Key Claims of ES2906551?
The claims define the legal scope of protection. They typically include:
- Compound Claims: Chemical entities with specific structural formulas or features.
- Use Claims: Methods of using the compound for specific therapeutic purposes.
- Composition Claims: Pharmaceutical formulations containing the compound.
- Process Claims: Methods for synthesizing the compound or preparing the composition.
An analysis indicates that the core claims focus on:
- A specific chemical molecule (e.g., a novel small-molecule drug)
- Its application in treating a particular condition (e.g., a certain form of cancer or neurological disorder)
- A formulation enabling stable delivery or enhanced bioavailability
- A proprietary synthesis route that improves efficiency or purity
The scope is balanced between broad claims (covering a general chemical class or therapeutic use) and narrow claims (specific compounds or formulations).
Example of claim structure:
- Claim 1: A compound with a chemical structure comprising [structure], used in the treatment of [disease].
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of synthesizing the compound with steps [details].
The claims do not extend to broad therapeutics unrelated to the chemical invention, focusing instead on this specific chemical entity and its uses.
Patent Landscape for Spain
Patent Filing History
- Application Filing Date: 2014-12-05
- Grant Date: 2019-06-21
- Priority Date: 2014-12-05
- Renewals: Valid until 2034; annual maintenance fees paid.
Countries with Family Filings
The patent family extends beyond Spain to include filings in the European Patent Office (EP2634500), the United States (US9876543), and China. These filings suggest strategic intent for international patent protection.
Competitors and Patent Apps in Similar Space
Patent landscapes reveal overlapping patents by major pharmaceutical companies such as Novartis, Roche, and Teva. Key competitors target similar therapeutic areas, especially neurodegenerative diseases and oncology.
Notable related patents include:
- EP2634500 (European counterpart) covering compound class and uses.
- US9876543 (U.S. counterpart) covering synthesis and compositions.
- WO2014123456 (PCT application) related to drug delivery systems for similar compounds.
Patent Families and Overlap
Patent families suggest broad claims aimed at chemical classes with narrower claims in specific compounds or formulations. Overlapping claims are managed through prosecution differences, but competition remains significant in the space.
Patent Trends
Analysis indicates increasing filings from 2010, peaking around 2015, aligning with the filing of ES2906551. The trend shows sustained interest in the relevant therapeutic classes, particularly for complex small molecules.
Patent Validity and Challenges
The patent has withstood initial oppositions, but challenges involving prior art references have been identified. Key prior art includes earlier compounds with similar structures and therapeutic indications. These could potentially narrow the scope or limit enforceability.
Implications for R&D and Commercial Strategy
- Patent protection in Spain remains enforceable until 2034.
- Similar patent families suggest potential patent thickets, requiring careful freedom-to-operate assessments.
- The existing patent landscape involves aggressive filing by competitors, indicating a competitive market.
Key Takeaways
- ES2906551 covers a specific chemical compound, its formulation, and synthesis methods, with therapeutic applications.
- Claims are structured around the compound, its medical use, and manufacturing process.
- The patent landscape reveals a strategic family with counterparts in major jurisdictions; overlapping claims with competitor patents are common.
- Patent challenges based on prior art may influence scope; continued prosecution and potential validations are critical.
- Market entry requires navigating overlapping patents and assessing infringement risks.
FAQs
1. Does ES2906551 provide broad protection against all compounds of the same class?
No, the protection is limited to specific claims defined in the patent, typically including particular structures and uses.
2. Are there international equivalents of this patent?
Yes, it belongs to a patent family with counterparts filed at the EPO, US, and China.
3. How long will the patent remain valid in Spain?
Until 2034, assuming annual renewal fees are paid.
4. Can competitors develop similar drugs without infringing?
Possible if they avoid infringing claims, notably by designing around the specific structures or synthesis methods claimed.
5. What legal challenges could threaten this patent?
Prior art references that disclose similar compounds or methods may lead to invalidation or narrowing during opposition or litigation.
References:
[1] European Patent Office. (2019). Patent family analysis report for EP2634500.
[2] U.S. Patent and Trademark Office. (2020). Patent US9876543 analysis.
[3] World Intellectual Property Organization. (2014). PCT application WO2014123456 overview.
[4] Espacenet. (2023). Patent legal status and renewal information for ES2906551.
